tiprankstipranks
PainReform (PRFX)
NASDAQ:PRFX
US Market
Holding PRFX?
Track your performance easily

PainReform (PRFX) Income Statement

151 Followers

PainReform Income Statement

Last quarter (Q4 2023), PainReform's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, PainReform's net income was $―. See PainReform’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----$ 0.00
Cost of Revenue
-$ 1.00M----
Gross Profit
-$ -1.00M----
Operating Expense
$ 3.94M$ 8.95M$ 8.87M$ 7.21M$ 1.67M$ 689.00K
Operating Income
$ -3.94M$ -9.95M$ -8.87M$ -7.21M$ -1.67M$ -689.00K
Net Non Operating Interest Income Expense
$ 78.00K$ 1.48M$ -147.00K$ -32.00K$ -2.16M$ -590.00K
Other Income Expense
$ -76.00K$ 1.73M$ -61.00K-$ -1.10M-
Pretax Income
$ -3.93M$ -9.34M$ -8.78M$ -7.24M$ -3.83M$ -1.28M
Tax Provision
-$ 8.00K$ 9.00K$ 6.00K$ 220.00K$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -3.93M$ -9.34M$ -8.79M$ -7.25M$ -4.05M$ -1.28M
Basic EPS
$ -0.37$ -7.14$ -0.82--$ -0.13
Diluted EPS
$ -0.37$ -7.14$ -0.82$ -44.40$ -75.00$ -0.13
Basic Average Shares
$ 21.42M$ 1.31M$ 10.66M$ 163.54K$ 54.06K$ 5.80M
Diluted Average Shares
$ 21.42M$ 1.31M$ 10.66M$ 163.20K$ 54.06K$ 5.80M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----$ 33.00K
Total Expenses
$ 3.94M$ 9.95M$ 8.87M$ 7.21M$ 1.67M$ 689.00K
Net Income From Continuing And Discontinued Operation
$ -3.93M$ -9.34M$ -8.79M$ -7.25M$ -4.05M$ -1.28M
Normalized Income
$ -3.86M$ -6.86M---$ -1.28M
Interest Expense
-----$ 541.00K
EBIT
$ -3.94M$ -9.34M$ -8.87M$ -7.21M$ -2.85M$ -738.00K
EBITDA
$ -3.93M$ -9.32M$ -8.85M$ -7.20M$ -2.85M$ -737.00K
Currency in USD

PainReform Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis